CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Palliative cancer care - pain - Management
Antimuscarinic: hyoscine butylbromide or mebeverine
Age from 16 years onwards
Hyoscine butylbromide sc inj: 10-20mg when required
Hyoscine butylbromide 20mg/1ml solution for injection ampoules
FOR SUBCUTANEOUS INJECTION. Give 0.5ml (10mg) to 1ml (20mg) as a subcutaneous dose, repeated after 2 hours if required for colic.
Supply 10 1ml ampoules.
Hyoscine butylbromide sc infusion: 40-300mg over 24 hours
Hyoscine butylbromide 20mg/1ml solution for injection ampoules
FOR CONTINUOUS SUBCUTANEOUS INFUSION. Give 2ml (40mg) to 15ml (300mg) over 24 hours via a syringe driver when required to reduce gastric secretions.
Supply 10 1ml ampoules.
Mebeverine tablets: 135mg three times a day
Mebeverine 135mg tablets
Take one tablet three times a day, preferably 20 minutes before meals.
Supply 84 tablets.
© NHS Institute for Innovation and Improvement